Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000049071
$420.97
-1.05% · delayed ~15 min
Last price from Oct 22, 2026
$50.79B market value
From HUMANA INC's FY2025 10-K, filed Feb 19, 2026 · read the filing
HUMANA sells insurance. It took in $129.66B last year, which makes it a very large company. Of every dollar it sells, about 1 cents is left as profit.
The financial picture is mixed, with profitability, growth and debt needing attention.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From HUMANA INC's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Free cash flow
$2.39B → $375.0M
Cash
$2.22B → $4.20B
Revenue
$117.76B → $129.66B
Operating income
$2.56B → $2.70B
Measured against FY2024, from the 10-K filed Feb 19, 2026
Deteriorated: -84.3%
$2.39B to $375.0MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
How the latest move compares (quote delayed ~15 min), and what was published around it
HUM fell 1.05% on the latest quote. The average Financials company tracked here moved +1.14%, and the S&P 500 −1.04%. That is 2.2 points below its sector and in line with the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 32 analysts covering this company, as of . Their views, not this site's.
Of 32 analysts publishing on this company, 8 say strong buy, 8 say buy, 15 say hold and 1 say sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 1 cents of every dollar of sales as profit, earning $1.19B last year.
Slowly. Sales grew 10.1% last year.
For every $1 it owes, it owns $1.57 in assets. Banks and insurers always carry high debt — that is how lending works — so this is normal for the industry and not comparable with other sectors.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 36 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 47% of the cash its operations generated. It has paid in each of the last 12 years.
GoodFigures from the FY2025 annual filing
Last year it earned $1.19B and generated $921.0M of cash from operations.
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 19, 2026Filing for FY2025 | FY202410-K · Feb 19, 2026Filing for FY2024 | FY202310-K · Feb 19, 2026Filing for FY2023 | FY202210-K · Feb 15, 2024Filing for FY2022 | FY202110-K · Feb 15, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $129.66B | $117.76B | $106.37B | $92.87B | $83.06B | +10.1% |
| Selling, general and administrative | $15.45B | $13.70B | $13.19B | $12.67B | $10.12B | +12.8% |
| Operating income | $2.70B | $2.56B | $4.01B | $3.80B | $3.15B | +5.5% |
| Operating marginOperating income ÷ revenueWhat is this? | 2.1% | 2.2% | 3.8% | 4.1% | 3.8% | −0.1 pts |
| Interest expense | $631.0M | $660.0M | $493.0M | $401.0M | $326.0M | −4.4% |
| Income before tax | $1.44B | $1.62B | $3.33B | $3.56B | $3.42B | −11.2% |
| Net income | $1.19B | $1.21B | $2.49B | $2.81B | $2.93B | −1.6% |
| Net marginNet income ÷ revenueWhat is this? | 0.9% | 1.0% | 2.3% | 3.0% | 3.5% | −0.1 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $9.85 | $10.00 | $19.92 | $22.16 | $22.76 | −1.6% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| HUMHUMANA INC · this page | 6.0/10 | 5/8 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Was granted or awarded shares — 2,549 shares
Holds 2,549 shares after this filing.
Was granted or awarded shares — 544 shares
Holds 544 shares after this filing.
Was granted or awarded shares
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingWrite down why you are following HUMANA INC, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
2 profitable stocks with promising prospects and 1 we find risky
Yahoo ·
Centene to Report Q3 Earnings: Buy, Sell or Hold the Stock?
Yahoo ·
What Healthcare Services Group (HCSG) Said on Its Q3 Earnings Call
Yahoo ·
SpaceX earnings roundup, Meta earnings preview, and tech trade fears
Yahoo ·
What Could Stop CVS Health Stock Over The Next Six Months?
Yahoo ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from HUM's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 19, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 6.0 | 5/8 | 10-K, filed Feb 19, 2026 |
| FY2024 | 6.0 | 6/8 | 10-K, filed Feb 20, 2025 |
| FY2023 | 6.0 | 6/8 | 10-K, filed Feb 15, 2024 |
| FY2022 | 6.0 | 6/8 | 10-K, filed Feb 16, 2023 |
| FY2021 | 6.0 | 3/8 | 10-K, filed Feb 17, 2022 |
| FY2020 | 7.3 | 5/8 | 10-K, filed Feb 18, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
5 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +89.1%
$2.22B to $4.20BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +10.1%
$117.76B to $129.66BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +5.5%
$2.56B to $2.70BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: +11.0%
$11.14B to $12.37BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Changed: -5.0%
$575.0M to $546.0MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q1 FY2026 against Q1 FY2025, from the 10-Q filed Apr 29, 2026 — read it.
Improved: +380.1%
$236.0M to $1.13BCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +23.5%
$32.11B to $39.65BSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +16.5%
$4.25B to $4.95BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +27.4%
$95.0M to $121.0MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Deteriorated: -12.9%
$2.01B to $1.75BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: −1.8 pts
6.3% to 4.4%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
6 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.3% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 16.0x — investors pay $16.0 for each $1 of trailing profit.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Reported annual figures
| 10.1% |
| 0.9% |
| 42.75x |
| 1.77x |
| UNHUNITEDHEALTH GROUP INC | 6.0/10 | 7/9 | 11.8% | 2.7% | 31.94x | 2.08x |
|---|
| ELVElevance Health, Inc. | 6.0/10 | 6/9 | 12.5% | 2.8% | 17.36x | 1.77x |
|---|
| CNCCENTENE CORP | 4.7/10 | 4/9 | 20.0% | -3.8% | — | 2.84x |
|---|
| MOHMOLINA HEALTHCARE, INC. | 6.0/10 | 4/9 | 11.7% | 1.0% | 23.41x | 2.83x |
|---|
| Median of peers | 6.0/10 | — | 12.2% | 1.9% | 23.41x | 2.45x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Holds 544 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Made a Regulation FD disclosure
Quarterly report on Form 10-Q
Read the filingHad a director or senior officer leave or join
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingQuarterly report for Q1 FY2026
Revenue +23.5% · Operating margin −1.8 pts · Free cash flow +380.1% — against Q1 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingHad a director or senior officer leave or join
Read the filingSigned a material agreement · Took on a direct financial obligation · Reported another event
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure
Read the filingAnnual report for FY2025
Revenue +10.1% · Free cash flow -84.3% · Cash +89.1% — against FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +11.1% · Operating margin −1.3 pts · Operating income -45.1% — against Q3 FY2024
Read the filingPrimary sources and further research